Intel stock extends gains after report of possible U.S. government stake
GALWAY - Medtronic plc (NYSE:MDT), the $117.8 billion healthcare technology giant, announced on Thursday that its board of directors has approved a cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026, representing a 3.06% yield at current prices.
The medical device maker said the dividend will be payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025.
This quarterly declaration aligns with the dividend increase that Medtronic announced in May 2025. The company noted that it has increased its annual dividend payment for 48 consecutive years, maintaining its position as a constituent of the S&P 500 Dividend Aristocrats index.
Medtronic, headquartered in Ireland, is a global healthcare technology company that develops and manufactures devices and therapies to treat 70 different health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems.
The announcement was made in a press release issued by the company.
In other recent news, Medtronic plc has received CE Mark approval to expand the indications for its MiniMed 780G automated insulin delivery system across Europe. This expansion now includes individuals as young as 2 years old, pregnant women, and people with type 2 insulin-requiring diabetes. The approval was supported by clinical data from the LENNY trial, which demonstrated safety and efficacy in young children with type 1 diabetes. Additionally, Medtronic received a boost as the Centers for Medicare and Medicaid Services (CMS) proposed coverage for its Renal Denervation (RDN) procedures. This proposal aligns with Medtronic’s clinical trial parameters and could enhance patient adoption once finalized. Following this development, William Blair reiterated a Market Perform rating on Medtronic, while JPMorgan maintained a Neutral rating, noting the proposal’s alignment with Medtronic’s Simplicity Spyral device. These developments highlight Medtronic’s ongoing efforts to expand its medical device offerings and improve patient care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.